Introduction Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, with a worldwide incidence of approximately 15 per million population. Imatinib mesylate is the first of a novel group of drugs that specifically target protein tyrosine kinases, which are central to the pathogenesis of human cancer. It has been approved for the treatment of gastrointestinal stromal tumors and chronic myeloid leukemia. Imatinib is associated with a variety of adverse cutaneous reactions, including urticaria, maculopapular exanthem, generalized exanthematous pustulosis, exfoliative dermatitis, and Stevens-Johnson syndrome, in which the management is challenging especially in the absence of alternative anticancer agents. We actually address the emerging imatinib resistance and intolerance to this drug. We describe a case of druginduced exanthem from imatinib mesylate and a review of literature.
|Disciplines associées||Laboratoire, Dermatologie|
|Auteurs associés||Arifi S, Brahmi S.A, El mrabet f Z, Mellas N, Mernissi FZ, El mesbahi O|
|Revue||J Gastrointest Cancer.|
|Référence Revue||45( 1): 71–73|